DNTH Dianthus Therapeutics Inc.
P/E
--
Forward P/E
--
Price/Sales
3340.2
Beta
0.082
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Point72 Exits $54M Stake in Dianthus Therapeutics (DNTH)
Steve Cohen's Point72 Asset Management has liquidated its entire position in Dianthus Therapeutics, a clinical-stage biotechnology company. According to...
Farallon Capital Exits Dianthus Therapeutics with $70.16M Stake Sale
In a significant portfolio shift, Farallon Capital Management fully exited its position in Dianthus Therapeutics (DNTH), selling all 836,000 of its shares. The...
RA Capital Exits $219M Stake in Dianthus Therapeutics (DNTH)
Prominent life sciences investor RA Capital Management has exited its entire position in Dianthus Therapeutics, a clinical-stage biotech firm. The fund sold...